Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations. The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.
Looming GLP-1 drug patent expirations draw generics firms
India and China are among the countries where knockoffs of Wegovy and Ozempic can be sold next year
GLP-1s may not affect obesity-related cancer risk: Study
A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers. The study, published Dec. 9 in Annals of Internal Medicine, is based on a review of 48 randomized controlled trials involving 94,245 […]
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes
Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott Reule Sean Pickthorn Stefanie Worwa Areef Ishani Robert Foley Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists […]
Pfizer inks $2B deal for early-stage GLP-1
Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist currently in phase 1 development for chronic weight management. YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, will complete the ongoing phase 1 clinical trial and grant Pfizer exclusive worldwide […]
Eli Lilly will be ‘aggressive’ in spending GLP-1 money, top dealmaker Van Naarden says
ORLANDO, Fla. — Eli Lilly’s new chief dealmaker is planning to spend its GLP-1 cash in an “aggressive” but responsible manner. Last month, Lilly’s president of oncology Jacob Van Naarden was
Pfizer continues renewed obesity push with $150M upfront for Fosun unit’s GLP-1 drug
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal.
Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)
GLP-1s and Cancer: Meta-analysis Shows Little or No Link
The systematic review and meta-analysis of 48 trials involving 94,245 individuals show little or no effect of GLP-1 RA treatment on the risk for obesity-related cancers. Medscape Medical News
SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response
SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, today announced the launch of two studies to validate its innovative GLP-1 patient stratification diagnostic platform. These studies aim to transform obesity and type 2 diabetes care by enabling healthcare providers to identify individuals most likely to benefit […]